Sacituzumab (powder) 

Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer^[1][2][3][4].

Sacituzumab (0.5 nM, 800 s) 具有非竞争性结合部位，并识别 TROP-2 抗原上的不同表位。此外，Sacituzumab 与 hIMB1636 的结合在癌细胞系中活性相似^[1]。
Sacituzumab (5 mg/mL, 48 h) 在 HEK-293T 细胞中，与 TROP-2 内的一个线性表位结合，这可能不会中断 TROP-2 分子在细胞表面的组装^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Sacituzumab (50 mg/kg, i.v., 每 5 天注射一次，注射 4 次) 在 MDAMB-468 异种移植瘤小鼠模型中显示出弱的抗肿瘤作用，而不显著减轻体重^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

145.52 kDa

1796566-95-4

无菌粉末

White to off-white

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhou DD, et al. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2[J]. Int J Biol Macromol. 2023 Dec 31;253(Pt 6):127105.  [Content Brief]

  [2]. Sun M, et al. Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2[J]. iScience. 2021 Sep 30;24(10):103190.  [Content Brief]

  [3]. Shih LB, et al. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer[J]. Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s.  [Content Brief]

  [4]. Bardia A, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148-1156.  [Content Brief]